EE592 Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide Versus Continuing on Entecavir in Chronic Hepatitis B Patients With Low-Level Viremia in Saudi Arabia

F Sanai,M Aljawad,As Alghamdi,A Khathlan,M Alghamdi,S Kozma,N Smith,F El Moustaid,S Jeyakumar,N Kachru

doi:10.1016/j.jval.2022.09.831

EE592 Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide Versus Continuing on Entecavir in Chronic Hepatitis B Patients With Low-Level Viremia in Saudi Arabia

F Sanai, M Aljawad + Show 8 more

Open Access

https://doi.org/10.1016/j.jval.2022.09.831

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Dec 1, 2022
License type: publisher-specific-oa

Affiliation: King Abdulaziz Medical City, King Fahad Specialist Hospital, King Fahad Hospital Jeddah, King Fahd Medical City, King Fahd Military Medical Complex, Gilead Sciences (United States)

#Entecavir In Chronic Hepatitis #Low-Level Viremia + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

EE592 Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide Versus Continuing on Entecavir in Chronic Hepatitis B Patients With Low-Level Viremia in Saudi Arabia

Full Text